Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Syndax Pharmaceuticals, Inc. - Common Stock
(NQ:
SNDX
)
14.44
+1.34 (+10.23%)
Delayed Quote
Updated: 12:34 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syndax Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Syndax (SNDX) Q3 2026 Earnings Call Transcript
↗
November 02, 2026
Revenue surged 82% year-over-year as Revuforj and Niktimvo drive commercial momentum.
Via
The Motley Fool
Topics
Earnings
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
↗
November 02, 2026
Syndax Pharmaceuticals (NASDAQ:SNDX) reported third-quarter 2026 total revenue of $83.3 million, an 82% increase from the prior-year period, as sales of its Revuforj leukemia treatment and...
Via
MarketBeat
Topics
Earnings
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
November 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
November 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimates
↗
August 04, 2026
Via
Chartmill
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
October 30, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation in November Investor Conferences
October 30, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
October 26, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
October 17, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
October 15, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
What's going on in today's after hours session
↗
October 12, 2026
Via
Chartmill
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
October 12, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation in September Investor Conferences
September 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax (SNDX) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
Revenue surged 92% year-over-year to $72.8 million, driven by Revuforj and Niktimvo.
Via
The Motley Fool
Topics
Earnings
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 05, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Q2 Earnings Call Highlights
↗
August 04, 2026
Syndax Pharmaceuticals (NASDAQ:SNDX) reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic...
Via
MarketBeat
Topics
Earnings
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
August 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
July 28, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
↗
July 14, 2026
Syndax Pharmaceuticals (NASDAQ:SNDX) used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell...
Via
MarketBeat
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
July 14, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
June 11, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
June 11, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
June 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
June 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
June 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
May 21, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation in Upcoming Investor Conferences
May 20, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
